Programme (nur in Englisch)

Funded projects
Men's Health Partners
"We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact." - Owen Sharp, CEO
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programmes
Mental health and suicide prevention
“We’re alarmed by the increasing number of men who take their own lives around the world. We are working to ensure all men and boys look after their mental health and are comfortable to reach out to others for support when they’re struggling.” 
Craig Martin, Global Director - Mental Health & Suicide Prevention programs
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programmes.

2014 Cancer Australia Priority driven Collaborative Cancer Research Scheme

Movember Funding to Date

AUD 500,000

What we seek to achieve

To reduce the impact of cancer in the community and improve outcomes for people affected by cancer. To work collaboratively with organisations that support cancer research to generate evidence, increase knowledge, and improve the translation of research into policy and practice.

Cancer Australia
Implemented by
Movember Foundation and Prostate Cancer Foundation of Australia
Project start date
January 2015
Project Status
In Progress

About the project

The PdCCRS aims to fund research in tumour areas that place a high burden of disease on the Australian community; fund applied cancer research projects that directly relate to the identified priorities of Cancer Australia and Prostate Cancer Foundation of Australia and fund research that can directly improve cancer outcomes by influencing clinical practice, policy and/or care.

Research funded through this scheme is Outcome/Impact-focused. Every project presents a clear pathway to translation and must be collaborative. These project grants demonstrate necessary collaborations that may be cross-disciplinary, national, multi-state or international, and the applicants describe the specific role of the key collaborators in the project. Importantly, PdCCRS grants engage consumers. Consumer involvement in the project must be substantive, meaningful and bi-directional.

Prostate Cancer Foundation of Australia entered into a co-funding agreement with Cancer Australia for a set amount of contribution which is matched dollar per dollar by Cancer Australia or/and other partners that participate in the scheme and fund prostate cancer research.

Cancer Australia announces the opening funding round and Prostate Cancer Foundation of Australia’s priorities of funding each year. Clinical trial applications and Young Investigator grants that address one or more priority areas of funding are peer reviewed by a minimum of two experts. A separate review committee convened by Cancer Australia assesses 10 additional questions that address impact, consumer participation, priority area, collaborative effort and overall milestones of the project.

This process identified three successful projects in two categories:

Clinical trials
Prof Paul Keall - The University of Sydney: SPARK: Stereotactic Prostate Aadaptive Radiotherapy utilising Kilovoltage intrafraction monitoring

The SPARK multicentre clinical trial will measure cancer targeting accuracy and patient outcomes in 48 prostate cancer patients. Patients will be treated with a novel cost effective real-time targeting radiotherapy technology developed and pioneered in Australia. The SPARK technology enables prostate cancer patients to be treated in 5 sessions rather than 40 sessions with comparable outcomes. The technology has potential for worldwide benefit for many other cancers e.g. lung, pancreas and liver.

Prof Ian Davis - Monash University - Pain Free TRUS B: A placebo-controlled, randomised trial of methoxyflurane to reduce the discomfort of prostate biopsy.

Diagnosis of prostate cancer usually requires a biopsy called a TRUS, which can be very painful. Many doctors use local anaesthetic but some doctors use sedation instead. This requires an anaesthetist and is costly. The “green whistle” (Penthrox) used in ambulances is safe and effective during TRUS. This trial will test whether Penthrox plus local anaesthetic improves outcomes for men having TRUS compared to local anaesthetic alone.

Young Investigator Category

Dr Brett Hollier – Queensland University of Technology Targeting neuropilin-1 to inhibit prostate cancer metastasis and therapy resistance.

This research study will investigate a protein involved in the spread and therapy resistance of prostate cancer. The results obtained from this project will reveal a new biomarker and therapeutic target to inhibit aggressive forms of prostate cancer.

Page 1 of 19